INFU vs BRT vs HCSG vs OPRX vs ACLX

For growth investors, OptimizeRx Corporation (OPRX) is the stronger pick with 18.

8% revenue growth year-over-year, versus -79. 4% for Arcellx, Inc. (ACLX). OptimizeRx Corporation (OPRX) offers the better valuation at 24. 6x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate InfuSystem Holdings, Inc. (INFU) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 24.

6x versus InfuSystem Holdings, Inc. at 28. 9x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x.

Over the past 5 years, Arcellx, Inc.

(ACLX) delivered a total return of +584. 9%, compared to -87. 3% for OptimizeRx Corporation (OPRX). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus HCSG's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcellx, Inc.

(ACLX) is the lower-risk stock at -0. 34β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately -774% more volatile than ACLX relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 4% versus 3% for BRT Apartments Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), OptimizeRx Corporation (OPRX) is pulling ahead at 18.

8% versus -79. 4% for Arcellx, Inc. (ACLX). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -103. 5% for Arcellx, Inc.. Over a 3-year CAGR, OPRX leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.

7% net margin versus -1027. 3% for Arcellx, Inc. — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRT leads at 11. 4% versus -1135. 6% for ACLX. At the gross margin level — before operating expenses — ACLX leads at 70. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.

0x forward P/E versus 21. 5x for InfuSystem Holdings, Inc. — 14. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.

In this comparison, BRT (7.

1% yield) pays a dividend. INFU, HCSG, OPRX, ACLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Arcellx, Inc.

(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 34), +584. 9% 10Y return). OptimizeRx Corporation (OPRX) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACLX: +584. 9%, OPRX: +110. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (INFU (Healthcare) and BRT (Real Estate) and HCSG (Healthcare) and OPRX (Healthcare) and ACLX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INFU is a small-cap quality compounder stock; BRT is a small-cap income-oriented stock; HCSG is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; ACLX is a small-cap quality compounder stock. BRT pays a dividend while INFU, HCSG, OPRX, ACLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.